85. Idiopathic interstitial pneumonia Clinical trials / Disease details
Clinical trials : 627 / Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000022037 | 2016/04/19 | 24/04/2016 | The pilot study of nivolumab for advanced NSCLC patients with IIPs which is clinically considered to be at low risk of acute exacerbation of IIPs. | The pilot study of nivolumab for advanced NSCLC patients with IIPs which is clinically considered to be at low risk of acute exacerbation of IIPs. - IP-NSCLC nivolumab study | Advanced NSCLC patients with IIPs | Nivolumab 3mg/kg, every 2 weeks | Kobe city medical center general hospital | NULL | Complete: follow-up complete | 20years-old | 100years-old | Male and Female | 6 | Not selected | Japan |